Press Release

February 24, 2012

Rundbuckstrasse 6
CH – 8212 Neuhausen am Rheinfall / Switzerland
www.lifewatch.com

LifeWatch announces joint development of new breakthrough test for its wireless cardiac monitoring platform

The testing technology will be deployed on LifeWatch wireless cardiac monitors in coming months

Neuhausen am Rheinfall/Switzerland – LifeWatch AG (SIX Swiss Exchange: LIFE), the leading wireless cardiac monitoring service provider in the U.S., announced today the joint development of additional Sympathetic and Parasympathetic testing with the ANSAR Group.

For the first time in the wireless cardiac monitoring industry, the treating physician will be able to measure individual parasympathetic and sympathetic responses of their patient. This information will be significant in providing additional clinical data for patients with Atrial Fibrillation, Syncope (fainting), Congestive Heart Failure, Cardiac Autonomic Neuropathy (associated with increased risk of mortality and morbidity) and Hypertension. These conditions together affect an estimated 99 million Americans[1]. An additional subset of patients who could benefit from this test includes millions of Americans who are currently prescribed Beta blockers.

"The Ansar test integrated with our ACT cardiac telemetry platform is a very important technological advance", stated Dr. Yacov Geva, Chairman and CEO of LifeWatch AG. "For the first time ever, a physician will be provided with invaluable clinical information about a patient's sympathetic and parasympathetic nervous system in a comprehensive arrhythmia report via an outpatient cardiac monitoring platform. The data generated from the Ansar test and LifeStar ACT cardiac monitor will assist in guiding therapy. Physicians will be able to diagnose vasovagal or neurocardiogenic syncope, orthostasis, arrhythmia or palpitations caused by surges in the parasympathetic or sympathetic tone with the LifeWatch ACT monitor. This has the potential to improve patient outcomes, reduce medication loads, hospitalizations, unnecessary deaths and overall healthcare costs. It is an honor for LifeWatch to be able to empower physicians with this capability."

The Ansar parasympathetic and sympathetic response monitoring test allows for the differential diagnosis of three main causes of syncope (neurogenic, vasovagal and cardiogenic), and other causes of dizziness (including orthostasis and arrhythmia). These individual measurements can be

recorded preceding an arrhythmic event, which will provide physicians with clear and precise documentation of the causes of underlying syncope, dizziness, arrhythmia, chest pain, or sleep disordered cardiac disturbances, etc., and aid the physician in the differential diagnosis and guiding therapy.

The easy-to-use test utilizes a LifeStar ACT wireless cardiac monitor enabling real-time viewing of the ECG before the patient is sent home for continued arrhythmia monitoring. The Ansar test, which is reimbursable, includes physiological parameters equivalent to a head-up tilt table test, and has demonstrated higher rates of specificity and sensitivity[2]. This test is encouraged by many of the leading professional medical societies in the United States, including the AHA, ADA, JDFI, AAN, AAFP, NIH. Published, peer-reviewed, parasympathetic and sympathetic response testing data shows how to optimize therapy for many difficult to treat conditions, including Atrial Fibrillation, Heart Failure, Hypertension, Dizziness (including syncope) and sleep disorders. This technology will be available in the US in the following months.

Sources: 1. Circulation 2012, 125:e2-e220, 2. Am Heart J 1997;134:316-20.

For further information please contact:
Sensus Investor and Public Relations GmbH, Zürich:
Tel+41 433665511 | Fax+41 43 366 55 12|Email lifewatch@sensus.ch

About LifeWatch AG
LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss Exchange (LIFE), Switzerland, is the leading healthcare technology and solution company, specializing in advanced telehealth systems and wireless remote patient monitoring services. LifeWatch services cater to individuals, ranging from high-risk and chronically ill patients, to consumers of health and wellness products. LifeWatch has subsidiaries in the United States, the Netherlands, Japan, the United Kingdom, Switzerland and Israel. LifeWatch AG is the parent company of LifeWatch Services Inc., a leading US-based cardiac monitoring service provider, and manufacturer of telecardiology products. LifeWatch is also introducing a new program for Home Sleep Testing of Obstructive Sleep Apnea (OSA) patients under the brand name NiteWatch. For additional information, please visit www.lifewatch.com.

Sign-up for customized E-mail alerts and documentation requests is available at http://production.investis.com/lifewatch/alert-service/

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS OF THE ISSUER.